1.709
price up icon17.05%   0.249
after-market 시간 외 거래: 1.75 0.041 +2.40%
loading
전일 마감가:
$1.46
열려 있는:
$1.33
하루 거래량:
24,616
Relative Volume:
1.12
시가총액:
$13.59M
수익:
-
순이익/손실:
$-17.93M
주가수익비율:
-0.9655
EPS:
-1.77
순현금흐름:
$-14.28M
1주 성능:
+30.46%
1개월 성능:
+15.47%
6개월 성능:
-5.58%
1년 성능:
+13.18%
1일 변동 폭
Value
$1.33
$1.709
1주일 범위
Value
$1.2318
$1.709
52주 변동 폭
Value
$1.12
$3.26

Cocrystal Pharma Inc Stock (COCP) Company Profile

Name
명칭
Cocrystal Pharma Inc
Name
전화
(786) 459-1831
Name
주소
19805 N. CREEK PARKWAY, BOTHELL, WA
Name
직원
11
Name
트위터
@cocrystalpharma
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
COCP's Discussions on Twitter

COCP을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
COCP
Cocrystal Pharma Inc
1.709 13.59M 0 -17.93M -14.28M -1.77
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Cocrystal Pharma Inc Stock (COCP) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2020-07-08 개시 H.C. Wainwright Buy

Cocrystal Pharma Inc 주식(COCP)의 최신 뉴스

pulisher
11:25 AM

Press Release Distribution & PR Platform - ACCESS Newswire

11:25 AM
pulisher
02:50 AM

Cocrystal Pharma (NASDAQ:COCP) Stock Price Up 3.3% – Here’s Why - Defense World

02:50 AM
pulisher
Apr 24, 2025

Cocrystal Pharma (COCP) Advances Norovirus Drug Candidate CDI-988 | COCP Stock News - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

Cocrystal Pharma Advances Norovirus Antiviral Candidate CDI-988 - TipRanks

Apr 24, 2025
pulisher
Apr 24, 2025

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - The Manila Times

Apr 24, 2025
pulisher
Apr 24, 2025

First-Ever Norovirus Treatment Tackles Dominant 2024 Variants: $60B Market Opportunity - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

Cocrystal Pharma Presents to Investment Community - TipRanks

Apr 23, 2025
pulisher
Apr 22, 2025

Aytu BioPharma Stock Price, Quotes and Forecasts - Benzinga

Apr 22, 2025
pulisher
Apr 16, 2025

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference - The Manila Times

Apr 16, 2025
pulisher
Apr 11, 2025

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For Vtama® - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Strategic Patent Filing Could Transform VTAMA's $233B Market Potential - Stock Titan

Apr 11, 2025
pulisher
Apr 10, 2025

OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR - Zacks Small Cap Research

Apr 10, 2025
pulisher
Apr 08, 2025

Cocrystal Pharma Approves 2025 Equity Incentive Plan - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA - openPR.com

Apr 08, 2025
pulisher
Apr 07, 2025

Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Apr 07, 2025
pulisher
Apr 05, 2025

COCRYSTAL PHARMA Earnings Preview: Recent $COCP Insider Trading, Hedge Fund Activity, and More - Nasdaq

Apr 05, 2025
pulisher
Apr 04, 2025

Q1 Earnings Forecast for COCP Issued By Zacks Small Cap - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

COCP stock touches 52-week low at $1.35 amid market fluctuations By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

COCP stock touches 52-week low at $1.35 amid market fluctuations - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

What is Zacks Small Cap’s Estimate for COCP Q3 Earnings? - Defense World

Apr 03, 2025
pulisher
Apr 01, 2025

COCP: Norovirus Challenge Study Planned for 2025… - MSN

Apr 01, 2025
pulisher
Mar 31, 2025

Cocrystal Pharma, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Influenza Pipeline: Advancing Innovation with 120+ Trailblazers Developing Transformative Therapies | DelveInsight - openPR.com

Mar 27, 2025
pulisher
Mar 24, 2025

Cocrystal Pharma Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView

Mar 24, 2025
pulisher
Mar 20, 2025

Hepatitis C Virus Infection Pipeline 2025: FDA Updates, Therapy - openPR

Mar 20, 2025
pulisher
Mar 20, 2025

Cocrystal Pharma (COCP) to Release Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 14, 2025

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times

Mar 14, 2025
pulisher
Mar 12, 2025

Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network

Mar 12, 2025
pulisher
Mar 12, 2025

Life Sciences Investor Forum Agenda Announced for March 13th - Morningstar

Mar 12, 2025
pulisher
Mar 07, 2025

Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga

Mar 07, 2025
pulisher
Mar 06, 2025

Cocrystal Pharma to Participate in a Fireside Chat at the - GlobeNewswire

Mar 06, 2025
pulisher
Mar 06, 2025

Kaltura to Host 2025 Investor Event - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Direct Access to Cocrystal Pharma Management: Key Details of Upcoming Zacks Analyst Forum - StockTitan

Mar 06, 2025
pulisher
Mar 04, 2025

Aptorum Gr Stock Price, Quotes and Forecasts | NASDAQ:APM - Benzinga

Mar 04, 2025
pulisher
Mar 03, 2025

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - ACCESS Newswire

Mar 03, 2025
pulisher
Feb 27, 2025

New Information Reveals Opportunity in Volatility -- Featured Research on Norsk Hydro, Paragon Offshore, Pure Biosciences and Cocrystal Pharma - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 21, 2025

Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight - The Malaysian Reserve

Feb 21, 2025
pulisher
Feb 11, 2025

Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Simply Wall St

Feb 11, 2025
pulisher
Feb 10, 2025

Honeywell International Inc’s (HON) Stock: A Long-Term Performance Analysis - The News Heater

Feb 10, 2025
pulisher
Feb 10, 2025

An In-Depth Look at BP plc ADR’s (BP) Stock Performance - The News Heater

Feb 10, 2025
pulisher
Feb 07, 2025

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times

Feb 07, 2025
pulisher
Feb 07, 2025

Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan

Feb 07, 2025
pulisher
Feb 03, 2025

Drugmakers prep for bird flu outbreak, despite continued low risk - PharmaVoice

Feb 03, 2025
pulisher
Jan 30, 2025

Cocrystal Pharma Extends Phase 2a Influenza Drug Study Amid Lower Infection Rates, Stock Near 52-Week High - HPBL

Jan 30, 2025

Cocrystal Pharma Inc (COCP) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
자본화:     |  볼륨(24시간):